ST-2191, an Anellated Bismorpholino Derivative of Oxy-Fingolimod, Shows Selective S1P
Animals
CHO Cells
Cricetulus
Fingolimod Hydrochloride
/ pharmacology
Humans
Lymphocyte Count
/ methods
Lysophospholipids
/ agonists
Mice
Mice, Inbred C57BL
Multiple Sclerosis
/ drug therapy
Phosphotransferases (Alcohol Group Acceptor)
/ metabolism
Receptors, Lysosphingolipid
/ metabolism
Signal Transduction
/ drug effects
Sphingosine
/ agonists
T-Lymphocytes
/ metabolism
S1P1 receptor
ST-2191
anellated bismorpholino
functional antagonism
lymphopenia
sphingosine 1-phosphate
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
24 Aug 2021
24 Aug 2021
Historique:
received:
30
07
2021
revised:
20
08
2021
accepted:
20
08
2021
entrez:
10
9
2021
pubmed:
11
9
2021
medline:
24
9
2021
Statut:
epublish
Résumé
Sphingosine 1-phosphate (S1P) is an extensively studied signaling molecule that contributes to cell proliferation, survival, migration and other functions through binding to specific S1P receptors. The cycle of S1P
Identifiants
pubmed: 34500564
pii: molecules26175134
doi: 10.3390/molecules26175134
pmc: PMC8433829
pii:
doi:
Substances chimiques
Lysophospholipids
0
Receptors, Lysosphingolipid
0
sphingosine 1-phosphate
26993-30-6
Phosphotransferases (Alcohol Group Acceptor)
EC 2.7.1.-
Fingolimod Hydrochloride
G926EC510T
Sphingosine
NGZ37HRE42
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 310030_135619
Organisme : Schweizerische Multiple Sklerose Gesellschaft
ID : n.a.
Organisme : Deutsche Forschungsgemeinschaft
ID : GRK2158, INST 208/690-1
Organisme : European Cooperation in Science and Technology
ID : CA15135, CA18133, CA18240
Organisme : Hochschulstiftung der Universität Bern
ID : 20/2020
Références
Proteins. 2009;77 Suppl 9:114-22
pubmed: 19768677
Am J Transplant. 2004 Jul;4(7):1019-25
pubmed: 15196057
Iran J Neurol. 2014 Jul 4;13(3):119-26
pubmed: 25422729
Br J Pharmacol. 2012 Nov;167(5):1035-47
pubmed: 22646698
Int J Mol Sci. 2020 Feb 13;21(4):
pubmed: 32069843
Science. 2002 Apr 12;296(5566):346-9
pubmed: 11923495
J Lipid Res. 2009 Apr;50 Suppl:S9-14
pubmed: 19098281
Neuropharmacology. 2021 Mar 15;186:108464
pubmed: 33460688
Biomol Ther (Seoul). 2021 Sep 1;29(5):492-497
pubmed: 33500376
Pharmacol Ther. 2018 May;185:34-49
pubmed: 29127024
Curr Top Microbiol Immunol. 2014;378:23-53
pubmed: 24728592
J Chem Inf Model. 2005 Jan-Feb;45(1):160-9
pubmed: 15667141
Chem Biol. 2005 Jun;12(6):703-15
pubmed: 15975516
Neurology. 2011 Feb 22;76(8 Suppl 3):S20-7
pubmed: 21339487
Biochem Pharmacol. 2008 May 15;75(10):1893-900
pubmed: 18321471
Matrix Biol. 2021 Apr;98:32-48
pubmed: 34015468
FEBS Lett. 1994 Nov 14;354(3):255-8
pubmed: 7957934
Pharmacol Res. 2020 Apr;154:104170
pubmed: 30776422
Neuropharmacology. 2014 Oct;85:314-27
pubmed: 24863045
Nat Rev Drug Discov. 2010 Nov;9(11):883-97
pubmed: 21031003
PLoS One. 2013 Sep 12;8(9):e74285
pubmed: 24069292
Inflamm Intest Dis. 2020 Nov;5(4):180-190
pubmed: 33313070
J Lipid Res. 2005 May;46(5):839-61
pubmed: 15722563
Nat Rev Immunol. 2008 Oct;8(10):753-63
pubmed: 18787560
Best Pract Res Clin Endocrinol Metab. 2018 Apr;32(2):83-91
pubmed: 29678288
J Biol Chem. 2002 Jun 14;277(24):21453-7
pubmed: 11967257
Pharmacol Ther. 2007 Jul;115(1):84-105
pubmed: 17561264
J Immunol Res. 2019 Dec 23;2019:5821589
pubmed: 31930150
Int J Mol Sci. 2020 Sep 04;21(18):
pubmed: 32899717
Drugs. 2021 Feb;81(2):207-231
pubmed: 33289881
Br J Pharmacol. 2014 Aug;171(15):3575-94
pubmed: 24602016
Drug Metab Dispos. 2021 May;49(5):405-419
pubmed: 33674268
Diabetologia. 2018 Jul;61(7):1650-1661
pubmed: 29671030
Neuropharmacology. 2016 Jun;105:341-350
pubmed: 26808312
Br J Pharmacol. 2016 Jun;173(11):1778-92
pubmed: 26990079